JP2012020996A5 - - Google Patents

Download PDF

Info

Publication number
JP2012020996A5
JP2012020996A5 JP2011149371A JP2011149371A JP2012020996A5 JP 2012020996 A5 JP2012020996 A5 JP 2012020996A5 JP 2011149371 A JP2011149371 A JP 2011149371A JP 2011149371 A JP2011149371 A JP 2011149371A JP 2012020996 A5 JP2012020996 A5 JP 2012020996A5
Authority
JP
Japan
Prior art keywords
compound
prolactin
cell
level
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011149371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012020996A (ja
JP5453355B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012020996A publication Critical patent/JP2012020996A/ja
Publication of JP2012020996A5 publication Critical patent/JP2012020996A5/ja
Application granted granted Critical
Publication of JP5453355B2 publication Critical patent/JP5453355B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011149371A 1998-05-12 2011-07-05 増殖性疾患を治療するための抗プロラクチン剤の使用 Expired - Lifetime JP5453355B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US60/085,128 1998-05-12
US24604199A 1999-02-05 1999-02-05
US09/246,041 1999-02-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000547993A Division JP5259896B2 (ja) 1998-05-12 1999-05-11 増殖性疾患を治療するための抗プロラクチン剤の使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013127119A Division JP2013224309A (ja) 1998-05-12 2013-06-18 増殖性疾患を治療するための抗プロラクチン剤の使用

Publications (3)

Publication Number Publication Date
JP2012020996A JP2012020996A (ja) 2012-02-02
JP2012020996A5 true JP2012020996A5 (enExample) 2012-09-13
JP5453355B2 JP5453355B2 (ja) 2014-03-26

Family

ID=26772335

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000547993A Expired - Lifetime JP5259896B2 (ja) 1998-05-12 1999-05-11 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2010223963A Withdrawn JP2011079821A (ja) 1998-05-12 2010-10-01 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2011149371A Expired - Lifetime JP5453355B2 (ja) 1998-05-12 2011-07-05 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2013127119A Withdrawn JP2013224309A (ja) 1998-05-12 2013-06-18 増殖性疾患を治療するための抗プロラクチン剤の使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000547993A Expired - Lifetime JP5259896B2 (ja) 1998-05-12 1999-05-11 増殖性疾患を治療するための抗プロラクチン剤の使用
JP2010223963A Withdrawn JP2011079821A (ja) 1998-05-12 2010-10-01 増殖性疾患を治療するための抗プロラクチン剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013127119A Withdrawn JP2013224309A (ja) 1998-05-12 2013-06-18 増殖性疾患を治療するための抗プロラクチン剤の使用

Country Status (11)

Country Link
US (2) US7115556B2 (enExample)
EP (2) EP1079851B1 (enExample)
JP (4) JP5259896B2 (enExample)
AT (1) ATE366114T1 (enExample)
AU (1) AU3895299A (enExample)
CA (1) CA2328520C (enExample)
DE (1) DE69936451T2 (enExample)
DK (1) DK1079851T3 (enExample)
ES (1) ES2288777T3 (enExample)
PT (1) PT1079851E (enExample)
WO (1) WO1999058142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1432064A (zh) * 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
ATE468104T1 (de) * 2002-06-12 2010-06-15 Oreal Mit silikonpolymeren und organischen geliermitteln strukturierte pflege- und/oder- makeup-zusammensetzung in starrer form
CA2509825A1 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
US9125880B2 (en) 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
EP2129793A1 (en) * 2007-03-20 2009-12-09 Institut National De La Sante Et De La Recherche Medicale Constitutively active mutants of the prolactin receptor
EP2167116A2 (en) * 2007-07-05 2010-03-31 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2009135056A2 (en) * 2008-04-30 2009-11-05 Monsanto Technology Llc Recombinant dna vectors for expression of human prolactin antagonists
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2400979B1 (en) 2009-02-26 2015-05-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
CA2788640A1 (en) * 2010-02-03 2011-08-11 Orbis Health Solutions Llc Method for sensitizing cells to cancer therapy
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
KR20190091290A (ko) 2016-11-29 2019-08-05 리제너론 파아마슈티컬스, 인크. Prlr 양성 유방암 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
WO1994019004A1 (en) 1993-02-19 1994-09-01 Genentech, Inc. Ligand antagonists for treatment of breast cancer
CN1053658C (zh) * 1994-04-06 2000-06-21 日本新药株式会社 氨基芪唑衍生物和药
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Similar Documents

Publication Publication Date Title
JP2012020996A5 (enExample)
HUS1900006I1 (hu) Kiméra antigén receptor módosított T-sejtek alkalmazása rák kezelésére
NO20210424A1 (no) Fremgangsmåte for å utføre brønnoperasjoner
DK2531110T3 (da) Apparat til dental computertomografi
CY1122132T1 (el) Μεθοδοι για τη μειωση των ρυθμων εξαρσης του ασθματος με χρηση μπενραλιζουμαμπης
HUE049886T2 (hu) Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
DK2658435T3 (da) Integreret dobbelt swept kilde til medicinsk oct afbildning
EP4052572C0 (en) TRANSGENIC MICE EXPRESSING CHIMERIC MOLECULES OF THE MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) II
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
PL2562183T3 (pl) Nowe epitopy immunogenne do immunoterapii
IN2015DN00885A (enExample)
ITMI20111404A1 (it) Supporto per articolazioni umane.
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
EA201201471A1 (ru) Модифицированные pyr/pyl-рецепторы, активированные ортогональными лигандами
CL2013003686A1 (es) Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
EP2535358A4 (en) CADAMINED WITH AN RADIOACTIVE METAL ANTIBODY TO CADHERINE
JP2012098270A5 (enExample)
IL241586B (en) Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy
EA201300733A1 (ru) Рекомбинантные микобактерии в качестве вакцины
EP2680919A4 (en) IMMUNOLOGICALLY MODIFIED CARBON NANOTONES FOR CANCER TREATMENT
EP2666122A4 (en) Optimized implementation of back projection for computed tomography (ct)
IT1401767B1 (it) Calzatura per la correzione di difetti anatomici o della deambulazione.
MX2015010566A (es) Metodos para la liberacion de las particulas similares a virus.
ZA201208194B (en) Marker vaccine for classical swine fever